MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

Search

Akebia Therapeutics Inc

Cerrado

SectorSalud

3.55 -2.47

Resumen

Variación precio

24h

Actual

Mínimo

3.49

Máximo

3.67

Métricas clave

By Trading Economics

Ingresos

29M

6.1M

Ventas

11M

57M

BPA

0.025

Margen de beneficio

10.66

Empleados

181

EBITDA

20M

14M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+106.04% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

345M

956M

Apertura anterior

6.02

Cierre anterior

3.55

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

163 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Akebia Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

1 jul 2025, 23:09 UTC

Ganancias

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1 jul 2025, 19:16 UTC

Adquisiciones, fusiones, absorciones

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1 jul 2025, 23:47 UTC

Charlas de Mercado

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1 jul 2025, 23:41 UTC

Charlas de Mercado

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1 jul 2025, 22:23 UTC

Adquisiciones, fusiones, absorciones

James Hardie: Deal Represents Implied Value of $8.4 Billion

1 jul 2025, 22:23 UTC

Adquisiciones, fusiones, absorciones

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1 jul 2025, 22:21 UTC

Adquisiciones, fusiones, absorciones

James Hardie Completes Acquisition of AZEK

1 jul 2025, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

1 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

1 jul 2025, 20:24 UTC

Ganancias

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1 jul 2025, 19:55 UTC

Charlas de Mercado

Oil Futures Resume Cautious Rally -- Market Talk

1 jul 2025, 19:27 UTC

Charlas de Mercado

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1 jul 2025, 19:12 UTC

Charlas de Mercado

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1 jul 2025, 19:01 UTC

Adquisiciones, fusiones, absorciones

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1 jul 2025, 18:41 UTC

Adquisiciones, fusiones, absorciones

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1 jul 2025, 18:33 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

1 jul 2025, 18:33 UTC

Charlas de Mercado

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1 jul 2025, 18:32 UTC

Charlas de Mercado

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1 jul 2025, 18:22 UTC

Charlas de Mercado

Remittances to Mexico Down in May -- Market Talk

1 jul 2025, 17:45 UTC

Charlas de Mercado

Seasonal Demand Supports Further Oil Gains -- Market Talk

1 jul 2025, 17:01 UTC

Adquisiciones, fusiones, absorciones

Danone Completed Acquisition of Majority Stake in Kate Farms

1 jul 2025, 16:55 UTC

Ganancias

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1 jul 2025, 16:27 UTC

Charlas de Mercado

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1 jul 2025, 16:25 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1 jul 2025, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

1 jul 2025, 15:48 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1 jul 2025, 15:46 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

1 jul 2025, 15:46 UTC

Charlas de Mercado

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1 jul 2025, 14:54 UTC

Charlas de Mercado

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1 jul 2025, 14:49 UTC

Charlas de Mercado

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Comparación entre iguales

Cambio de precio

Akebia Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

106.04% repunte

Estimación a 12 meses

Media 7.5 USD  106.04%

Máximo 8 USD

Mínimo 7 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Akebia Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

2

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.345 / N/ASoporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

163 / 380 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.